Autoimmunity. 2002 May;35(3):183-90.

Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG.

Oshima M, Deitiker P, Ashizawa T, Atassi MZ.

Source

Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA. moshima@bcm.tmc.edu

Abstract

An animal model of myasthenia gravis (MG), termed experimental autoimmune MG (EAMG), can be induced in C57BL/6 (B6, H-2b) mice by immunization with Torpedo californica acetylcholine receptor (tAChR). We have investigated the effect of vaccination with MHC class II peptide I-A beta(b)62-76 on clinical EAMG and on T cell and antibody (Ab) responses against tAChR. B6 mice were vaccinated with the peptide (25 microg/mouse) four times prior to two injections with tAChR. The incidence of clinical EAMG in vaccinated mice was 14% (3 out of 22 mice) compared to 48% (17 out of 35 mice) in control non-vaccinated or PBS-immunized mice. The T cells of the vaccinated group showed lower proliferative responses to tAChR and to T-cell epitope-containing tAChR alpha-chain peptides than the T cells of controls. In addition, the Ab responses in the vaccinated group was also lower against tAChR and some of the B-cell epitope-containing tAChR alpha-chain peptides.

PMID:: 12389643; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Related Immune Epitope Information - Immune Epitope Database and Analysis Resource

Supplemental Content

Save items

Related citations in PubMed

Review On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope. [Crit Rev Immunol. 2001]
Review On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ, Oshima M, Deitiker P. Crit Rev Immunol. 2001; 21(1-3):1-27.
T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses. [Autoimmunity. 2000]
T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses.
Oshima M, Atassi MZ. Autoimmunity. 2000; 32(1):45-55.
T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products. [Autoimmunity. 1998]
T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products.
Oshima M, Yokoi T, Deitiker P, Atassi MZ. Autoimmunity. 1998; 27(2):79-90.
Effect of amino acid substitutions within the region 62-76 of I-A beta b on binding with and antigen presentation of Torpedo acetylcholine receptor alpha-chain peptide 146-162. [J Immunol. 1995]
Effect of amino acid substitutions within the region 62-76 of I-A beta b on binding with and antigen presentation of Torpedo acetylcholine receptor alpha-chain peptide 146-162.
Oshima M, Atassi MZ. J Immunol. 1995 May 15; 154(10):5245-54.
Review Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides. [Crit Rev Immunol. 1997]
Review Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
Atassi MZ, Oshima M. Crit Rev Immunol. 1997; 17(5-6):481-95.

See reviews... See all...

Cited by 1 PubMed Central article

Cancer treatment using peptides: current therapies and future prospects. [J Amino Acids. 2012]
Cancer treatment using peptides: current therapies and future prospects.
Thundimadathil J. J Amino Acids. 2012; 2012:967347. Epub 2012 Dec 20.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Vaccination with a MHC class II peptide attenuates cellular and humoral response...
Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG.
Autoimmunity. 2002 May ;35(3):183-90.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: